We focused our analysis on breast cancer patients who received chemotherapy due to the larger sample size in the dataset compared to that for patients who received endocrine or anti-HER2 therapies (n = 507 versus n = 160 and n = 151, respectively). The gene discussed is ERBB2; the disease is breast carcinoma.